CN1142780C - 药用组合物 - Google Patents
药用组合物 Download PDFInfo
- Publication number
- CN1142780C CN1142780C CNB971949611A CN97194961A CN1142780C CN 1142780 C CN1142780 C CN 1142780C CN B971949611 A CNB971949611 A CN B971949611A CN 97194961 A CN97194961 A CN 97194961A CN 1142780 C CN1142780 C CN 1142780C
- Authority
- CN
- China
- Prior art keywords
- weight
- preparation
- hydroxypropyl emthylcellulose
- methocel
- premium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 7
- -1 hydroxypropyl Chemical group 0.000 claims description 139
- 238000002360 preparation method Methods 0.000 claims description 90
- 229920003091 Methocel™ Polymers 0.000 claims description 62
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 42
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 38
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims description 37
- DCVQBRUIZDUKJS-UHFFFAOYSA-N heptane;thiophene Chemical compound C=1C=CSC=1.CCCCCCC DCVQBRUIZDUKJS-UHFFFAOYSA-N 0.000 claims description 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 27
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 25
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 25
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 21
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 21
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 21
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 21
- 239000001509 sodium citrate Substances 0.000 claims description 14
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000002270 ergogenic effect Effects 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 239000011363 dried mixture Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 12
- 238000013268 sustained release Methods 0.000 abstract description 4
- 239000012730 sustained-release form Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003349 gelling agent Substances 0.000 description 13
- 239000004567 concrete Substances 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 229920003072 Plasdone™ povidone Polymers 0.000 description 4
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 235000003642 hunger Nutrition 0.000 description 4
- 230000037351 starvation Effects 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 229950010118 cellacefate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
活性组分(a) | 460.51 | 57.6 |
乳糖NF | 152.62 | 19.1 |
微晶纤维素NF | 50.87 | 6.3 |
METHOCELE50LV Premium(b) | 120.00 | 15.0 |
纯净水(c) | 适量 | - |
硬脂酸镁NF | 16.0 | 2.0 |
活性组分(a) | 460.51 | 57.6 |
乳糖NF | 81.74 | 10.2 |
微晶纤维素NF | 81.75 | 10.2 |
METHOCELE50LV Premium(b) | 120.00 | 15.0 |
METHOCELE4M Premium CR(d) | 40.00 | 5.0 |
纯净水(c) | 适量 | - |
硬脂酸镁NF | 16.0 | 2.0 |
活性组分(a) | 345.38 | 43.2 |
乳糖NF | 49.31 | 6.2 |
微晶纤维素NF | 49.31 | 6.2 |
柠檬酸钠 | 100.00 | 12.5 |
METHOCELK100LV Premium CR(b) | 200.00 | 25.0 |
METHOCELK4M Premium CR(c) | 40.00 | 5.0 |
纯净水(d) | 适量 | - |
硬脂酸镁NF | 16.00 | 2.0 |
活性组分(a) | 345.38 | 43.2 |
乳糖NF | 89.31 | 11.1 |
微晶纤维素NF | 89.31 | 11.1 |
柠檬酸钠 | 100.00 | 12.5 |
METHOCELK100LV Premium CR(b) | 120.00 | 15.0 |
METHOCELE4M Premium CR(c) | 40.00 | 5.0 |
纯净水(d) | 适量 | - |
硬脂酸镁NF | 16.00 | 2.0 |
活性组分(a) | 345.38 | 43.2 |
乳糖NF | 69.31 | 8.7 |
微晶纤维素NF | 69.31 | 8.7 |
柠檬酸钠 | 100.00 | 12.5 |
METHOCELK100LV Premium CR(b) | 200.00 | 25.0 |
纯净水(d) | 适量 | - |
硬脂酸镁NF | 16.00 | 2.0 |
活性组分(a) | 345.38 | 43.2 |
聚维酮USP(b) | 40.00 | 5.0 |
微晶纤维素NF | 38.62 | 4.8 |
柠檬酸钠 | 200.00 | 25.0 |
METHOCELE50LV Premium(c) | 80.00 | 10.0 |
METHOCELE4M Premium CR(d) | 80.00 | 10.0 |
纯净水(e) | 适量 | - |
硬脂酸镁NF | 16.00 | 2.0 |
活性组分(a) | 345.38 | 43.2 |
聚维酮USP(b) | 40.00 | 5.0 |
微晶纤维素NF | 38.62 | 4.8 |
柠檬酸钠 | 200.00 | 25.0 |
METHOCELE50LV Premium(c) | 80.00 | 10.0 |
METHOCELE4M Premium CR(d) | 80.00 | 10.0 |
纯净水(e) | 适量 | - |
硬脂酸镁NF | 16.0 | 2.0 |
活性组分(a) | 345.38 | 43.2 | 345.38 | 43.2 | 345.38 | 43.2 |
乳糖NF | 109.31 | 13.7 | 69.31 | 8.7 | 49.31 | 6.2 |
微晶纤维素NF | 109.31 | 13.7 | 69.31 | 8.7 | 49.31 | 6.2 |
柠檬酸钠 | 100.00 | 12.5 | 100.00 | 12.5 | 100.00 | 12.5 |
METHOCELE100LVPremium CR(b) | 120.00 | 15.0 | 200.00 | 25.0 | 200.00 | 25.00 |
METHOCELE4M | - | - | - | - | 40.00 | 5.0 |
Premium CR(c) | ||||||
纯净水(d) | 适量 | - | 适量 | - | 适量 | - |
硬脂酸镁NF | 16.00 | 2.0 | 16.00 | 2.0 | 16.00 | 2.0 |
活性组分(a) | 345.38 | 43.2 |
聚维酮USP(b) | 80.00 | 10.00 |
柠檬酸钠USP | 100.00 | 12.5 |
微晶纤维素NF | 138.62 | 17.3 |
METHOCELE4M Premium CR(c) | 120.00 | 15.0 |
纯净水(d) | 适量 | - |
硬脂酸镁NF | 16.0 | 2.0 |
片芯 | mg/片 |
活性组分(a) | 115.13 |
聚维酮USP(b) | 8.33 |
磷酸二钙二水合物USP | 10.00 |
微晶纤维素NF | 32.88 |
羟乙酸淀粉钠NF | 8.33 |
乳糖NF | 22.33 |
硬脂酸镁NF | 3.00 |
纯净水(c) | 适量 |
包衣 | mg/片 |
羟丙基甲基纤维素2910 USP(d) | 5.00 |
聚乙二醇400 NF | 1.00 |
氧化铁黄NF | 0.15 |
二氧化钛USP | 1.85 |
Claims (23)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9611328.7A GB9611328D0 (en) | 1996-05-31 | 1996-05-31 | Pharmaceutical compositions |
GB9611328.7 | 1996-05-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100033798A Division CN1511532A (zh) | 1996-05-31 | 1997-05-27 | 药用组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1219879A CN1219879A (zh) | 1999-06-16 |
CN1142780C true CN1142780C (zh) | 2004-03-24 |
Family
ID=10794541
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100033798A Pending CN1511532A (zh) | 1996-05-31 | 1997-05-27 | 药用组合物 |
CNA2006101016820A Pending CN101006985A (zh) | 1996-05-31 | 1997-05-27 | 药用组合物 |
CNB971949611A Expired - Lifetime CN1142780C (zh) | 1996-05-31 | 1997-05-27 | 药用组合物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100033798A Pending CN1511532A (zh) | 1996-05-31 | 1997-05-27 | 药用组合物 |
CNA2006101016820A Pending CN101006985A (zh) | 1996-05-31 | 1997-05-27 | 药用组合物 |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP0907364B1 (zh) |
JP (5) | JP2000511170A (zh) |
CN (3) | CN1511532A (zh) |
AR (1) | AR003662A1 (zh) |
AT (1) | ATE222105T1 (zh) |
AU (1) | AU727219B2 (zh) |
BR (1) | BR9709271A (zh) |
CA (1) | CA2251944C (zh) |
CZ (1) | CZ293760B6 (zh) |
DE (1) | DE69714739T2 (zh) |
DK (1) | DK0907364T3 (zh) |
EG (1) | EG24118A (zh) |
ES (1) | ES2182079T3 (zh) |
GB (2) | GB9611328D0 (zh) |
HR (1) | HRP970299B1 (zh) |
HU (1) | HU225152B1 (zh) |
ID (1) | ID18352A (zh) |
IL (1) | IL127222A (zh) |
MY (1) | MY120120A (zh) |
NO (1) | NO327801B1 (zh) |
NZ (1) | NZ332198A (zh) |
PL (1) | PL189887B1 (zh) |
PT (1) | PT907364E (zh) |
RU (1) | RU2201754C2 (zh) |
SI (1) | SI0907364T1 (zh) |
SK (1) | SK284131B6 (zh) |
TR (1) | TR199802483T2 (zh) |
TW (1) | TW550076B (zh) |
UA (1) | UA50772C2 (zh) |
WO (1) | WO1997045124A1 (zh) |
ZA (1) | ZA974735B (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
SE0003126D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Method of treatment |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
SE0102855D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
JP3624954B1 (ja) * | 2001-11-07 | 2005-03-02 | 藤沢薬品工業株式会社 | 分散不良薬物の溶出性を改善する方法 |
TW200735878A (en) * | 2005-11-18 | 2007-10-01 | Astrazeneca Ab | Pharmaceutical compositions |
EP1976487A2 (en) | 2006-01-25 | 2008-10-08 | Astron Research Limited | Sustained release dosage form of phenothiazine derivatives containing channelizer |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
PT1958617E (pt) | 2007-02-14 | 2010-10-28 | Lesvi Laboratorios Sl | Composições farmacêuticas contendo fumarato de quetiapina |
EP2131817A2 (en) | 2007-03-09 | 2009-12-16 | Synthon B.V. | Pharmaceutical composition of quetiapine fumarate |
US20080287418A1 (en) * | 2007-05-16 | 2008-11-20 | Astrazeneca Ab | Extended Release Compositions and Methods for Their Manufacture |
DE202009018024U1 (de) | 2008-08-01 | 2010-12-09 | Krka Tovarna Zdravil, D.D., Novo Mesto | Quetiapin-Zusammensetzung |
EP2153834A3 (en) | 2008-08-07 | 2010-02-24 | Farmaprojects, S.A. | Extended release pharmaceutical compositions comprising quetiapine salts |
DE102008046650A1 (de) | 2008-09-10 | 2010-03-11 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Quetiapin enthaltende Retardtablette |
EP2373319B1 (en) * | 2009-01-05 | 2013-07-31 | Torrent Pharmaceuticals Limited | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof |
WO2010089259A2 (en) | 2009-02-04 | 2010-08-12 | Woerwag R&D Gmbh | Sustained release composition containing quetiapine |
EP2233130A1 (en) * | 2009-03-23 | 2010-09-29 | Genepharm (Europe) Trading Limited | A sustained release oral composition of an antipsychotic agent |
AR076907A1 (es) * | 2009-05-13 | 2011-07-20 | Wyeth Llc | Composiciones con liberacion rapida de farmaco |
WO2011132008A2 (en) | 2010-04-22 | 2011-10-27 | EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság | Controlled release pharmaceutical composition |
WO2011154118A1 (en) | 2010-06-07 | 2011-12-15 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Quetiapine prolonged-release tablets |
DE102010033527A1 (de) | 2010-08-05 | 2012-02-09 | Acino Pharma Ag | Quetiapin-Tabletten |
TR201008261A1 (tr) | 2010-10-08 | 2012-04-24 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Kontrollü salım gerçekleştiren ketiapin formülasyonları |
CN102218042A (zh) * | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
DE102011115690A1 (de) | 2011-10-11 | 2013-04-11 | Acino Pharma Ag | Quetiapin enthaltende Formulierungen |
CN102406606B (zh) * | 2011-11-29 | 2013-01-23 | 海南美大制药有限公司 | 富马酸喹硫平脂质体固体制剂 |
WO2014037022A1 (en) | 2012-09-10 | 2014-03-13 | Pharmathen S.A. | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |
EP2848244A1 (en) | 2013-09-16 | 2015-03-18 | Yildiz Özsoy Erginer | Extended release tablet formulations of quetiapine |
CA2988918A1 (en) * | 2015-06-19 | 2016-12-22 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
CN106187873B (zh) * | 2016-07-25 | 2019-11-05 | 宜春学院 | 一种芳胺基烷基氧类化合物及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US4775535A (en) * | 1986-04-04 | 1988-10-04 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
ATE71833T1 (de) * | 1986-11-03 | 1992-02-15 | Schering Corp | Labetalol tablette mit verzoegerter wirkstoffabgabe. |
IE59540B1 (en) * | 1987-01-09 | 1994-03-09 | Elan Corp | Sustained release capsule or tablet formulation |
GB8705574D0 (en) * | 1987-03-10 | 1987-04-15 | Ici Plc | Preparation of thiazepine compound |
US4983398A (en) * | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
SE9003902D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | Solid dosage forms of a drug |
IT1256651B (it) * | 1992-12-11 | 1995-12-12 | Giancarlo Santus | Composizione farmaceutica a rilascio controllato in sospensione liquida |
JP3116970B2 (ja) * | 1991-06-12 | 2000-12-11 | 三菱東京製薬株式会社 | ペミロラストカリウムの徐放性製剤 |
IT1256393B (it) * | 1992-11-17 | 1995-12-04 | Inverni Della Beffa Spa | Forme matriciali multistrato per il rilascio controllato di principi attivi |
US5393765A (en) * | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
AU707454B2 (en) * | 1994-05-13 | 1999-07-08 | Smithkline Beecham Corporation | Method and composition for increasing calcium uptake |
-
1996
- 1996-05-31 GB GBGB9611328.7A patent/GB9611328D0/en active Pending
-
1997
- 1997-05-15 GB GBGB9709761.2A patent/GB9709761D0/en active Pending
- 1997-05-27 HU HU9902194A patent/HU225152B1/hu unknown
- 1997-05-27 PL PL97330223A patent/PL189887B1/pl not_active IP Right Cessation
- 1997-05-27 CA CA002251944A patent/CA2251944C/en not_active Expired - Lifetime
- 1997-05-27 SI SI9730410T patent/SI0907364T1/xx unknown
- 1997-05-27 PT PT97924103T patent/PT907364E/pt unknown
- 1997-05-27 WO PCT/GB1997/001432 patent/WO1997045124A1/en active IP Right Grant
- 1997-05-27 UA UA98127026A patent/UA50772C2/uk unknown
- 1997-05-27 CZ CZ19983880A patent/CZ293760B6/cs not_active IP Right Cessation
- 1997-05-27 SK SK1639-98A patent/SK284131B6/sk not_active IP Right Cessation
- 1997-05-27 BR BR9709271A patent/BR9709271A/pt not_active Application Discontinuation
- 1997-05-27 IL IL12722297A patent/IL127222A/xx not_active IP Right Cessation
- 1997-05-27 CN CNA2004100033798A patent/CN1511532A/zh active Pending
- 1997-05-27 DK DK97924103T patent/DK0907364T3/da active
- 1997-05-27 DE DE69714739T patent/DE69714739T2/de not_active Expired - Lifetime
- 1997-05-27 JP JP09541846A patent/JP2000511170A/ja active Pending
- 1997-05-27 ES ES97924103T patent/ES2182079T3/es not_active Expired - Lifetime
- 1997-05-27 EP EP97924103A patent/EP0907364B1/en not_active Expired - Lifetime
- 1997-05-27 NZ NZ332198A patent/NZ332198A/xx not_active IP Right Cessation
- 1997-05-27 RU RU98123601/14A patent/RU2201754C2/ru active
- 1997-05-27 CN CNA2006101016820A patent/CN101006985A/zh active Pending
- 1997-05-27 TR TR1998/02483T patent/TR199802483T2/xx unknown
- 1997-05-27 AU AU29675/97A patent/AU727219B2/en not_active Expired
- 1997-05-27 CN CNB971949611A patent/CN1142780C/zh not_active Expired - Lifetime
- 1997-05-27 AT AT97924103T patent/ATE222105T1/de active
- 1997-05-28 HR HR970299A patent/HRP970299B1/xx not_active IP Right Cessation
- 1997-05-28 EG EG47397A patent/EG24118A/xx active
- 1997-05-28 MY MYPI97002306A patent/MY120120A/en unknown
- 1997-05-29 ZA ZA9704735A patent/ZA974735B/xx unknown
- 1997-05-30 AR ARP970102352A patent/AR003662A1/es active IP Right Grant
- 1997-05-30 ID IDP971846A patent/ID18352A/id unknown
- 1997-06-04 TW TW086107689A patent/TW550076B/zh not_active IP Right Cessation
-
1998
- 1998-11-27 NO NO19985539A patent/NO327801B1/no not_active IP Right Cessation
-
2006
- 2006-03-15 JP JP2006071695A patent/JP2006152006A/ja active Pending
-
2007
- 2007-02-09 JP JP2007030991A patent/JP2007119495A/ja active Pending
-
2011
- 2011-11-07 JP JP2011243832A patent/JP5888549B2/ja not_active Expired - Lifetime
-
2014
- 2014-06-12 JP JP2014121055A patent/JP2014167026A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1142780C (zh) | 药用组合物 | |
CN1211086C (zh) | 雷诺嗪持续释放制剂 | |
CN1278678C (zh) | 具有高生物利用率的非诺贝特药物组合物及其制备方法 | |
CN1298317C (zh) | 坦洛新片剂 | |
CN1170542C (zh) | 奥卡西平包膜片剂 | |
CN1607947A (zh) | 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物 | |
CN1638771A (zh) | 3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型 | |
CN1651087A (zh) | 有机化合物的联合形式 | |
CN1443069A (zh) | 雷诺嗪缓释制剂 | |
CN1780618A (zh) | 替米沙坦钠盐的药物制剂 | |
CN1323200A (zh) | 5ht4激动剂或拮抗剂的新型口服制剂 | |
EP2964200B1 (en) | Formulations of organic compounds | |
CN1903182A (zh) | 小型化盐酸沙格雷酯经口给药制剂 | |
CN1684681A (zh) | 比西发定制剂 | |
CN1285738A (zh) | 卡维地洛的新的口服剂型 | |
CN1915216A (zh) | 坦度螺酮及其衍生物的新用途、及含有坦度螺酮的组合物 | |
CN100336511C (zh) | 口服罗红霉素控释制剂 | |
CN1188113C (zh) | 含有profen和其它活性化合物的组合的药物混合物 | |
CN1188131C (zh) | 苯二氮卓类药物口服脉冲释药系统及其制备方法 | |
CN1552327A (zh) | 口服左氧氟沙星控释药物组合物 | |
CN1527705A (zh) | 含有ltb4拮抗剂的药物制剂 | |
CN1217655C (zh) | 黄藤素缓释制剂 | |
CN1305379A (zh) | 治疗方法 | |
CN1526383A (zh) | 一种甲福明和格列本脲的固体口服剂型及其制备方法 | |
CN1634083A (zh) | 阿司匹林口腔崩解片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SYNGENTA CO., LTD. Free format text: FORMER NAME OR ADDRESS: ZENECA LTD |
|
CP03 | Change of name, title or address |
Address after: surrey Patentee after: Zeneca Ltd. Address before: London, England, England Patentee before: Zeneca Limited |
|
ASS | Succession or assignment of patent right |
Owner name: ASTRAZENECA (UK) LIMITED Free format text: FORMER OWNER: SYNGENTA CO., LTD. Effective date: 20061229 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20061229 Address after: London, England Patentee after: Astrazeneca UK Ltd. Address before: surrey Patentee before: Zeneca Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20040324 |
|
CX01 | Expiry of patent term |